药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Idursulfase
Methadyl acetate
The risk or severity of adverse effects can be increased when Methadyl acetate is combined with DPDPE.
Idursulfase
Alvimopan
The risk or severity of adverse effects can be increased when DPDPE is combined with Alvimopan.
Idursulfase
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of DPDPE.
Idursulfase
Suvorexant
DPDPE may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Idursulfase
Sodium oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of DPDPE.
Idursulfase
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with DPDPE.
Idursulfase
Rotigotine
DPDPE may increase the sedative activities of Rotigotine.
Idursulfase
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of DPDPE.
Idursulfase
Paraldehyde
DPDPE may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Idursulfase
Methotrimeprazine
DPDPE may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Ranibizumab
Filgotinib
The serum concentration of Pitavastatin can be increased when it is combined with Filgotinib.
Ranibizumab
Satralizumab
The serum concentration of Pitavastatin can be decreased when it is combined with Satralizumab.
Ranibizumab
Fostemsavir
The serum concentration of Pitavastatin can be increased when it is combined with Fostemsavir.
Ranibizumab
Selpercatinib
The serum concentration of Pitavastatin can be increased when it is combined with Selpercatinib.
Ranibizumab
Capmatinib
The serum concentration of Pitavastatin can be increased when it is combined with Capmatinib.
Ranibizumab
Tafamidis
The serum concentration of Pitavastatin can be increased when it is combined with Tafamidis.
Ranibizumab
Darolutamide
The serum concentration of Pitavastatin can be increased when it is combined with Darolutamide.
Ranibizumab
Lasmiditan
The serum concentration of Pitavastatin can be increased when it is combined with Lasmiditan.
Ranibizumab
Alpelisib
The serum concentration of Pitavastatin can be decreased when it is combined with Alpelisib.
Ranibizumab
Chenodeoxycholic acid
The metabolism of Pitavastatin can be decreased when combined with Chenodeoxycholic acid.